Literature DB >> 22561710

The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia.

Vanessa Stevens1, Thomas P Lodise, Brian Tsuji, Meagan Stringham, Jill Butterfield, Elizabeth Dodds Ashley, Kristen Brown, Alan Forrest, Jack Brown.   

Abstract

OBJECTIVE: Bloodstream infections due to methicillin-resistant Staphylococcus aureus (MRSA) have been associated with significant risk of in-hospital mortality. The acute physiology and chronic health evaluation (APACHE) II score was developed and validated for use among intensive care unit (ICU) patients, but its utility among non-ICU patients is unknown. The aim of this study was to determine the ability of APACHE II to predict death at multiple time points among ICU and non-ICU patients with MRSA bacteremia.
DESIGN: Retrospective cohort study. PARTICIPANTS: Secondary analysis of data from 200 patients with MRSA bacteremia at 2 hospitals.
METHODS: Logistic regression models were constructed to predict overall in-hospital mortality and mortality at 48 hours, 7 days, 14 days, and 30 days using APACHE II scores separately in ICU and non-ICU patients. The performance of APACHE II scores was compared with age adjustment alone among all patients. Discriminatory ability was assessed using the c-statistic and was compared at each time point using χ(2) tests. Model calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test.
RESULTS: APACHE II was a significant predictor of death at all time points in both ICU and non-ICU patients. Discrimination was high in all models, with c-statistics ranging from 0.72 to 0.84, and was similar between ICU and non-ICU patients at all time points. APACHE II scores significantly improved the prediction of overall and 48-hour mortality compared with age adjustment alone.
CONCLUSIONS: The APACHE II score may be a valid tool to control for confounding or for the prediction of death among ICU and non-ICU patients with MRSA bacteremia.

Entities:  

Mesh:

Year:  2012        PMID: 22561710     DOI: 10.1086/665731

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  14 in total

1.  Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Jason C Gallagher; Safia Kuriakose; Kevin Haynes; Peter Axelrod
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Authors:  D M Martirosov; M R Bidell; M P Pai; M H Scheetz; S L Rosenkranz; T P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2017-04-02       Impact factor: 2.803

3.  A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Sarah C J Jorgensen; Abdalhamid M Lagnf; Sahil Bhatia; Michael J Rybak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-08       Impact factor: 3.267

4.  Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.

Authors:  M Souli; I Karaiskos; A Masgala; L Galani; E Barmpouti; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-16       Impact factor: 3.267

5.  Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Evan J Zasowski; Trang D Trinh; Kimberly C Claeys; Anthony M Casapao; Noor Sabagha; Abdalhamid M Lagnf; Kenneth P Klinker; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Jessica B Cprek; Jason C Gallagher
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

7.  Development of a mortality prediction formula due to sepsis/severe sepsis in a medical intensive care unit.

Authors:  Anant Mohan; Prajowl Shrestha; Randeep Guleria; Ravindra Mohan Pandey; Naveet Wig
Journal:  Lung India       Date:  2015 Jul-Aug

8.  Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients.

Authors:  Marcela A Ferrada; Andrew A Quartin; Daniel H Kett; Michele I Morris
Journal:  BMC Anesthesiol       Date:  2013-10-30       Impact factor: 2.217

9.  ICG-liver test versus new biomarkers as prognostic markers for prolonged length of stay in critically ill patients - a prospective study of accuracy for prediction of length of stay in the ICU.

Authors:  Bernhard Zoller; Katharina Spanaus; Rahel Gerster; Mario Fasshauer; Paul A Stehberger; Stephanie Klinzing; Athanasios Vergopoulos; Arnold von Eckardstein; Markus Béchir
Journal:  Ann Intensive Care       Date:  2014-07-08       Impact factor: 6.925

10.  Simplified risk stratification criteria for identification of patients with MRSA bacteremia at low risk of infective endocarditis: implications for avoiding routine transesophageal echocardiography in MRSA bacteremia.

Authors:  P Buitron de la Vega; P Tandon; W Qureshi; Y Nasr; R Jayaprakash; S Arshad; D Moreno; G Jacobsen; K Ananthasubramaniam; M Ramesh; M Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.